John Geddes
Corporate Officer/Principal presso CARDIOL THERAPEUTICS INC.
Profilo
John A.
Geddes is currently the Vice President-Business Development at Cardiol Therapeutics, Inc. He previously worked as the Director-Business Development at Luminex Corp., the Associate Director-Business Development at Novo Nordisk Canada, Inc., and the VP-Business Development & Marketing at Vasogen, Inc. Mr. Geddes holds an MBA from Richard Ivey School of Business and undergraduate degrees from Queen’s University Belfast and Queen's University.
Posizioni attive di John Geddes
Società | Posizione | Inizio |
---|---|---|
CARDIOL THERAPEUTICS INC. | Corporate Officer/Principal | 01/01/2022 |
Precedenti posizioni note di John Geddes
Società | Posizione | Fine |
---|---|---|
Novo Nordisk Canada, Inc.
Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Corporate Officer/Principal | - |
LUMINEX CORPORATION | Corporate Officer/Principal | - |
Formazione di John Geddes
Queen's University | Undergraduate Degree |
Richard Ivey School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Aziende private | 3 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Luminex Corp.
Luminex Corp. Medical SpecialtiesHealth Technology Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The firm's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX. | Health Technology |
Novo Nordisk Canada, Inc.
Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- John Geddes